IS6375A - Lyfjagjöf til öftrunar á blöðruhálskrabbameini - Google Patents

Lyfjagjöf til öftrunar á blöðruhálskrabbameini

Info

Publication number
IS6375A
IS6375A IS6375A IS6375A IS6375A IS 6375 A IS6375 A IS 6375A IS 6375 A IS6375 A IS 6375A IS 6375 A IS6375 A IS 6375A IS 6375 A IS6375 A IS 6375A
Authority
IS
Iceland
Prior art keywords
administration
prostate cancer
stimulation
cancer stimulation
prostate
Prior art date
Application number
IS6375A
Other languages
English (en)
Inventor
S. Steiner Mitchell
Raghow Sharan
Original Assignee
The University Of Tennessee Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tennessee Research Corporation filed Critical The University Of Tennessee Research Corporation
Publication of IS6375A publication Critical patent/IS6375A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS6375A 1999-11-08 2002-05-08 Lyfjagjöf til öftrunar á blöðruhálskrabbameini IS6375A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43620899A 1999-11-08 1999-11-08
US09/531,472 US6413533B1 (en) 1998-05-07 2000-03-20 Method for chemoprevention of prostate cancer
PCT/US2000/030658 WO2001034117A1 (en) 1999-11-08 2000-11-08 A method for chemoprevention of prostate cancer

Publications (1)

Publication Number Publication Date
IS6375A true IS6375A (is) 2002-05-08

Family

ID=27030854

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6375A IS6375A (is) 1999-11-08 2002-05-08 Lyfjagjöf til öftrunar á blöðruhálskrabbameini

Country Status (19)

Country Link
US (1) US6413533B1 (is)
EP (1) EP1229903A4 (is)
JP (1) JP2003513903A (is)
KR (2) KR20060130788A (is)
CN (1) CN1331463C (is)
AU (1) AU782444B2 (is)
BG (1) BG65794B1 (is)
CA (1) CA2390295C (is)
CZ (1) CZ20021763A3 (is)
HR (1) HRP20020422A2 (is)
HU (1) HUP0203304A3 (is)
IL (1) IL149545A0 (is)
IS (1) IS6375A (is)
MX (1) MXPA02004676A (is)
NO (1) NO20022221L (is)
PL (1) PL354726A1 (is)
SK (1) SK8162002A3 (is)
WO (1) WO2001034117A1 (is)
YU (1) YU43002A (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
MXPA04005112A (es) 2001-11-29 2005-04-29 Gtx Inc Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno.
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
KR20030061474A (ko) * 2002-01-14 2003-07-22 한미약품 주식회사 서트랄린 제조용 중간체로서 사용되는 시스-라세메이트화합물의 개선된 제조방법
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7321881B2 (en) * 2004-02-27 2008-01-22 Aureon Laboratories, Inc. Methods and systems for predicting occurrence of an event
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
WO2005050563A2 (en) * 2003-11-17 2005-06-02 Aureon Biosciences Corporation Pathological tissue mapping
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
JP5123935B2 (ja) * 2006-05-22 2013-01-23 ホルモス メディカル リミテッド 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
WO2009040824A2 (en) * 2007-09-24 2009-04-02 Ganga Raju Gokaraju Anti-adipogenic compositions containing piper betel and dolichos bifloras
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
CA2811258C (en) 2010-09-16 2019-10-15 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
JP3566741B2 (ja) * 1992-10-27 2004-09-15 日本化薬株式会社 自己免疫疾患治療薬
DK0671909T3 (da) * 1992-12-01 2001-03-19 Biotie Therapies Corp Syndecanstimulering af cellulær differentiering
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
CA2168584C (en) 1993-08-09 2008-10-14 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
ZA982819B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA984650B (en) 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
CN1275911A (zh) * 1997-08-15 2000-12-06 杜克大学 一种预防或治疗雌激素依赖性疾病及失调的方法
GB9805868D0 (en) * 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
SI1003496T1 (en) * 1998-05-07 2005-10-31 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
CA2346333A1 (en) * 1998-10-06 2000-04-13 Usda-Ars-Ott Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin

Also Published As

Publication number Publication date
KR20020070276A (ko) 2002-09-05
AU1588401A (en) 2001-06-06
HRP20020422A2 (en) 2004-04-30
EP1229903A1 (en) 2002-08-14
JP2003513903A (ja) 2003-04-15
BG106738A (en) 2003-02-28
KR100793721B1 (ko) 2008-01-10
EP1229903A4 (en) 2006-06-07
HK1057000A1 (en) 2004-03-12
AU782444B2 (en) 2005-07-28
US6413533B1 (en) 2002-07-02
HUP0203304A2 (hu) 2003-02-28
CN1331463C (zh) 2007-08-15
HUP0203304A3 (en) 2006-02-28
WO2001034117A1 (en) 2001-05-17
CA2390295C (en) 2009-09-29
NO20022221L (no) 2002-06-28
NO20022221D0 (no) 2002-05-08
MXPA02004676A (es) 2004-09-10
PL354726A1 (en) 2004-02-09
IL149545A0 (en) 2002-11-10
CN1420765A (zh) 2003-05-28
CA2390295A1 (en) 2001-05-17
YU43002A (sh) 2005-09-19
WO2001034117A9 (en) 2002-05-10
CZ20021763A3 (cs) 2003-02-12
BG65794B1 (bg) 2009-12-31
KR20060130788A (ko) 2006-12-19
SK8162002A3 (en) 2003-03-04

Similar Documents

Publication Publication Date Title
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
NO20021400L (no) Terapeutiske kinazolinderivater
DK1637127T3 (da) Terapeutisk mikroskum
NO20014105L (no) Texanderivater for målrettet cancerterapi
DE60022714D1 (de) Implantierbarer Herzschrittmacher
DE60124021D1 (de) Implantierbare Stimulationsleitung
PL354540A1 (en) Drugs for the treatment of malignant tumours
IS5025A (is) Samtengd efnasambönd nytsamleg við meðhöndlunina á krabbameini í blöðruhálskirtli
NO20022221D0 (no) Metode for kjemisk forhindring av prostatakreft
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
IS5502A (is) Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
MXPA03003011A (es) Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
ATE310515T1 (de) Verbesserte krebsbehandlung mit temozolomid
ZA200110436B (en) Therapeutic use of melatonin.
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
NO20021976L (no) Selektiv leverterapi
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer
ZA200203166B (en) Treatment of cancer.
DE60016737D1 (de) Implantierbarer herzschrittmacher
DK1535622T3 (da) Melanomterapi
FIU990263U0 (fi) Rapuneula